MHRA-100177-PIP01-21-M01 (update)

Key Facts

PIPS Key Facts
Active Substance
  • INFLUENZA B/YAMAGATA/16/88-LIKE VIRUS ANTIGEN
  • INFLUENZA A/ (H3N2)-LIKE VIRUS ANTIGEN
  • INFLUENZA B/VICTORIA/2/87-LIKE VIRUS ANTIGEN
  • INFLUENZA A/ (H1N1)-LIKE VIRUS ANTIGEN
Invented Name
  • FLUCELVAX TETRA
  • FLUCELVAX TETRA
  • FLUCELVAX QUADRIVALENT
  • FLUCELVAX QUAD
  • FLUCELVAX QUAD
  • FLUCELVAX QUAD
  • FLUCELVAX QUAD
  • FLUCELVAX TETRA
PIP Number MHRA-100177-PIP01-21-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Suspension for injection
Therapeutic area
Therapeutic area:
  • Vaccines
Conditions / Indications
Conditions / Indications:
  • Prevention of influenza
Route(s) of administration
Route(s) of administration:
  • Intramuscular use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):INFLUENZA B/YAMAGATA/16/88-LIKE VIRUS ANTIGENINFLUENZA A/ (H3N2)-LIKE VIRUS ANTIGENINFLUENZA B/VICTORIA/2/87-LIKE VIRUS ANTIGENINFLUENZA A/ (H1N1)-LIKE VIRUS ANTIGEN.pdf
Published Date 21/10/2022